The Real-world Treatment Patterns and Clinical Outcomes in Moderate-to-severe Atopic Dermatitis (AD) Patients Receiving Abrocitinib
This study is to describe the real-world treatment patterns and clinical outcomes in moderate-to-severe AD patients receiving abrocitinib over a 12-month observation period, and to describe patient demographic and baseline characteristics.
⁃ Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study:
• Patients aged ≥12 years
• Patients with confirmed diagnosis of moderate-to-severe AD as assessed by the physician
• Patients for whom the physician's decision has been made to newly prescribe abrocitinib in usual clinical practice conditions
• Evidence of a personally signed and dated informed consent/assent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study